Key statistics dashboard for Ernexa Therapeutics Inc. (ERNA). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer.
Stock Data
| Price | $3.91 |
| Market Cap | $1M |
| Enterprise Value | -$3.5M |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.21 |
| Price / Book | 1.45 |
| P/S | 0.00 |
| EV/EBITDA | 0.20 |
| EV/Sales | 0.00 |
| EV/FCF | 0.39 |
| P/FCF | -0.14 |
| Earnings Yield | -264.99% |
| FCF Yield | -722.83% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -305.85% |
| Return on Assets | -194.09% |
| Return on Invested Capital | -328.05% |
| Return on Capital Employed | -346.94% |
Financial Health
| Current Ratio | 2.01 |
| Quick Ratio | 2.01 |
| Cash Ratio | 1.71 |
| Debt / Equity | 0.11 |
| Debt / Assets | 5.53% |
| Net Debt / EBITDA | 0.27 |
| Interest Coverage | -378.61 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -62.89 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 2.70 |
| Cash per share | 4.25 |
| FCF per share | -7.50 |
| Tangible Book Value per share | 2.70 |
| Dividend per share | 0.00 |
Related companies: ADAP · AEMD · AEON · DWTX · LNAI · MBRX · MPLT
Explore sector: Healthcare · Biotechnology
More sections of ERNA: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks